News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,125 Results
Type
Article (39001)
Company Profile (278)
Press Release (644846)
Section
Business (203868)
Career Advice (1987)
Deals (35365)
Drug Delivery (84)
Drug Development (80781)
Employer Resources (168)
FDA (16085)
Job Trends (14801)
News (344521)
Policy (32431)
Tag
Academia (2530)
Alliances (49046)
Alzheimer's disease (1219)
Approvals (16005)
Artificial intelligence (122)
Bankruptcy (353)
Best Places to Work (11487)
Biotechnology (196)
Breast cancer (109)
Cancer (965)
Cardiovascular disease (82)
Career advice (1657)
Cell therapy (209)
Clinical research (64001)
Collaboration (339)
Compensation (173)
COVID-19 (2523)
C-suite (85)
Data (940)
Diabetes (140)
Diagnostics (6114)
Earnings (84484)
Employer resources (146)
Events (109124)
Executive appointments (256)
FDA (16550)
Funding (301)
Gene therapy (153)
GLP-1 (566)
Government (4320)
Healthcare (18659)
Infectious disease (2602)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16278)
Job creations (3624)
Job search strategy (1415)
Layoffs (409)
Legal (7849)
Lung cancer (158)
Manufacturing (159)
Medical device (13154)
Medtech (13159)
Mergers & acquisitions (19122)
Metabolic disorders (375)
Neuroscience (1463)
NextGen Class of 2024 (6502)
Non-profit (4463)
Northern California (1302)
Obesity (223)
Opinion (176)
Patents (96)
People (56166)
Phase I (19868)
Phase II (28180)
Phase III (21032)
Pipeline (320)
Postmarket research (2553)
Preclinical (8453)
Radiopharmaceuticals (234)
Rare diseases (189)
Real estate (5888)
Regulatory (21458)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1163)
Startups (3572)
United States (12274)
Vaccines (541)
Weight loss (163)
Date
Today (251)
Last 7 days (1049)
Last 30 days (3264)
Last 365 days (35571)
2024 (31151)
2023 (40076)
2022 (51173)
2021 (55717)
2020 (54089)
2019 (46541)
2018 (35022)
2017 (32114)
2016 (31482)
2015 (37555)
2014 (31322)
2013 (26350)
2012 (28576)
2011 (29269)
2010 (27336)
Location
Africa (713)
Arizona (188)
Asia (37056)
Australia (6040)
California (2934)
Canada (1205)
China (224)
Colorado (127)
Connecticut (130)
Europe (79326)
Florida (414)
Georgia (104)
Illinois (319)
Indiana (187)
Kansas (96)
Maryland (543)
Massachusetts (2372)
Michigan (146)
Minnesota (257)
New Jersey (867)
New York (874)
North Carolina (675)
Northern California (1302)
Ohio (129)
Pennsylvania (780)
South America (1091)
Southern California (1163)
Texas (402)
Utah (84)
Washington State (335)
684,125 Results for "bioventures inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease
NephroDI Therapeutics (NephroDI), a near-clinical stage pharmaceutical company focusing on kidney disorders, announces a Series A investment from life sciences VC Sound Bioventures.
June 20, 2024
·
4 min read
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
Sound Bioventures announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic viral therapies.
April 17, 2024
·
4 min read
Press Releases
Arrivo BioVentures Begins Phase 1 Study of SP-624, the First Potential Treatment Specifically for Women with Major Depressive Disorder
October 10, 2024
·
3 min read
Press Releases
Altius Bioventures Launches The CGT Industry Atlas, Mapping out the Cell and Gene Therapy Technology Innovation Landscape
September 11, 2024
·
2 min read
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, announced it has successfully closed its latest financing round, raising a total of £19M with the addition of Sound Bioventures as a new investor.
April 17, 2024
·
4 min read
Pharm Country
Harmonic Discovery Announces Licensing Agreement with BioVentures and UCSF for FLT3 Mutated AML Development Program
Harmonic Discovery announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia from BioVentures and UC San Francisco.
January 30, 2024
·
3 min read
Business
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
G1 Therapeutics, Inc., a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter Bioventures, announced a global licensing agreement for lerociclib for radioprotective uses.
May 22, 2024
·
5 min read
Policy
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, announced that the Egyptian Drug Authority has approved the manufacturing and distribution of AVT02 a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases, under the trade name Adalimumab-EVA™.
August 29, 2023
·
10 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Policy
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, the healthcare division of Yas Holding LLC, announced that the Saudi Food & Drug Authority has approved the manufacturing and distribution of AVT02, a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases.
January 24, 2023
·
10 min read
1 of 68,413
Next
